SalaryGuide
AboutPricingFor Employers

Marketing jobs

3 marketing jobs

Moderna logo
6 weeks ago

Associate Director, Marketing - Oncology

Moderna

Cambridge, MA (Hybrid)Full time$143K/yr – $257K/yr
Moderna logo
4 months ago

2026 Co-Op, Project ONRAMP Brand & Communications

Moderna

Cambridge, MA (Hybrid)Full time$20/hr – $60/hr
Moderna logo
5 months ago

2026 Co-Op, Project ONRAMP Brand & Communications

Moderna

Cambridge, MA (On-site)Full time$20/hr – $60/hr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

3 jobs
Moderna logo

Associate Director, Marketing - Oncology

Moderna

Cambridge, MA (Hybrid)

$143K/yr - $257K/yrIn-houseFull-timeMid level6+ years exp.
6 weeks ago
Moderna logo

2026 Co-Op, Project ONRAMP Brand & Communications

Moderna

Cambridge, MA (Hybrid)

$20/hr - $60/hrIn-houseFull-timeIntern/new grad
4 months ago
Moderna logo

2026 Co-Op, Project ONRAMP Brand & Communications

Moderna

Cambridge, MA (On-site)

$20/hr - $60/hrIn-houseFull-timeIntern/new grad
5 months ago
Moderna logo
Moderna

Associate Director, Marketing - Oncology

Cambridge, MA (Hybrid)

$143K/yr – $257K/yrMid Level6+ years expFull time

Posted 6 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own and optimize commercial operating models with a data driven spine, aligning field execution, launches across indications, and partnerships for speed and impact.

  • Launch readiness planning across indications with integrated workplans and governance.
  • Forecasting and performance management that scale marketing and sales across teams.
  • Cross functional alignment on incentives, CRM adoption, analytics, and real time performance monitoring.

Job Description

Responsibilities

  • Lead the development and optimization of commercial operating models to support both standalone and partnership-based commercialization scenarios
  • Drive launch readiness planning across multiple indications, including integrated workplans, governance, and execution tracking
  • Establish marketing/sales scalable processes for forecasting, performance management, and field execution
  • Oversee commercial KPIs and dashboards, translating insights into actionable recommendations
  • Support field force strategy and implementation, including sizing, structure, and territory alignment and ongoing efforts to ensure optimization
  • Partner with teams to help build and operationalize incentive compensation frameworks aligned to business objectives
  • Lead development of sales force capabilities, including onboarding, training curricula, and continuous skill-building programs with relevant cross-functional partners
  • Drive adoption of CRM and field tools to enhance productivity and customer engagement
  • Partner with analytics teams to deliver advanced insights supporting decision-making (e.g., targeting, resource allocation)
  • Implement tools and processes for real-time performance monitoring

Requirements

  • Bachelor’s degree required; MBA or advanced degree preferred
  • 6+ years of experience in biopharma commercial operations, commercial excellence, marketing operations, consulting, or related functions
  • Experience in oncology commercialization and/or launch execution preferred
  • Demonstrated success in sales force effectiveness, marketing operations, or commercial excellence roles
  • Data‑driven, execution‑focused, and comfortable making trade‑offs in key decisions
  • Strategic thinking skills with the ability to synthesize complex data and insights into clear, actionable recommendations for field teams and senior stakeholders
  • Proven ability to partner cross-functionally and influence stakeholders across Commercial, Medical, Market Access, Finance, and other key stakeholders
  • Analytics capabilities including how to effectively measure launch success
  • Strong communication and presentation skills
  • Curiosity mindset, and a passion for contributing to a transformative company that is Bold, Relentless, Curious, and Collaborative.

Benefits

  • Competitive healthcare, plus voluntary benefit programs to support your unique needs
  • A holistic approach to well-being, with access to fitness, mindfulness, and mental health support
  • Family planning benefits, including fertility, adoption, and surrogacy support
  • Generous paid time off, including vacation, volunteer days, sabbatical, global recharge days, and a discretionary year-end shutdown
  • Savings and investments to help you plan for the future
  • Location-specific perks and extras
Moderna logo

Moderna

3.5 Glassdoor

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.This Moderna page is not the appropriate place to report adverse events (side-effects) for any products. If you are or someone you know is experiencing a side effect, please reach out to your healthcare professional. Moderna is continuously monitoring the safety of its products. We encourage you to report any side effects directly to us at 1‐866‐MODERNA (1‐866‐663‐3762).

Founded in 2010
Cambridge, Massachusetts, USA
www.modernatx.com/?tc=soc_7y8qkt&cc=1004
54% recommend to a friend
68% CEO approval

Traffic Signals

Monthly Google Ads Budget
$6K

Marketing Team

Median Career Experience
17.5 years
Median Tenure
3.1 years
Marketing Roles Posted (Last 30 Days)
2

People

Founders / CEO

Kenneth Chien
Kenneth Chien
Co-Founder
At the company for 16 years 7 months
Noubar Afeyan
Noubar Afeyan
Co-Founder and Chairman
At the company for 16 years 7 months

HR / Recruitment

Nels Hanson
Nels Hanson
Director, Executive Search - Talent Acquisition Lead, R&D
At the company for 3 years 4 months
Alissa Parmelee
Alissa Parmelee
Head of Global Talent, Learning, and Talent Acquisition
At the company for 5 years 5 months

Marketing Leadership

Amy Mahery
Amy Mahery
Chief Marketing Officer
At the company for 1 year 6 months
Emily Morris-McCarthy
Emily Morris-McCarthy
VP, Head of Global Marketing, Oncology
At the company for 10 months
Alissa Parmelee
Alissa Parmelee
Head of Global Talent, Learning, and Talent Acquisition
At the company for 5 years 5 months
Anand Gupte
Anand Gupte
Head of Global Marketing Operations and Innovation
At the company for 3 years 10 months

Funding

Total Funding
$4.6B
Last Raise
$54.3M
Grant, 3 months ago

Funding History

  • Dec 2025
    Grant • $54.3M
  • Nov 2025
    Post IPO Debt • $600M
  • Jul 2024
    Grant • $176M

Recent News

Moderna is the S&P 500's most shorted stock: Here's why
Nov 24, 2025 • Yahoo Finance
Moderna is most shorted stock in S&P 500 as Americans skip jabs
Nov 23, 2025 • Financial Times
Moderna Cans 3 mRNA Vaccines, Secures $1.5B Loan in Quest for 10% Growth
Nov 21, 2025 • BioSpace
Moderna's reshaping rolls on with 3 more pipeline purges
Nov 20, 2025 • Fierce Biotech
Moderna takes out $1.5B loan, outlines commercial and R&D strategy in bid to break even by 2028
Nov 20, 2025 • Fierce Pharma
Moderna secures $1.5B lifeline as it looks to break even in 2028
Nov 20, 2025 • BioPharma Dive
Moderna Trims Pipeline and Takes On $1.5 Billion Loan as Cash Worries Loom
Nov 20, 2025 • Barron's
Moderna takes $1.5 billion loan, expects 10% revenue growth next year
Nov 20, 2025 • Reuters
Moderna blueprints $140M plant in bid to bring end-to-end mRNA production to US
Nov 19, 2025 • Fierce Pharma
Moderna to complete US mRNA manufacturing network with $140 million investment
Nov 19, 2025 • Reuters
The Moderna, Inc. (NASDAQ:MRNA) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Nov 9, 2025 • Yahoo Finance
How Recent Analyst Shifts Are Reshaping the Story for Moderna Investors
Nov 7, 2025 • Yahoo Finance
Moderna's phase 3 norovirus study heads north again after struggling to find cases down south
Nov 6, 2025 • Fierce Biotech
The Once and Future Moderna
Nov 6, 2025 • statnews.com
Moderna trims annual expenses outlook on lower production costs, R&D cuts
Nov 6, 2025 • Reuters
IDWeek 2025: No signal for myocarditis in updated Moderna mRNA COVID vaccine
Nov 5, 2025 • European AIDS Treatment Group
Moderna: Focus On Cancer Vaccines, Not Buyout (NASDAQ:MRNA)
Oct 31, 2025 • Seeking Alpha
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline
Oct 30, 2025 • Yahoo Finance
How Moderna, the company that helped save the world, unraveled
Oct 30, 2025 • statnews.com
Moderna scraps mRNA vaccine in congenital CMV on Phase III failure
Oct 23, 2025 • Clinical Trials Arena
No Signal for Myocarditis in Updated Moderna COVID Vax
Oct 23, 2025 • Medscape
Despite a tough year, Moderna forges ahead with cancer therapies
Oct 23, 2025 • statnews.com
Moderna halts development of birth defect vaccine after trial setback
Oct 22, 2025 • Reuters
Moderna scraps congenital virus program after vaccine shows little protective effect in phase 3
Oct 22, 2025 • Fierce Biotech
Moderna says key study of its CMV vaccine, expected to be its next big win, failed
Oct 22, 2025 • statnews.com
Moderna Drops Vaccine for Birth Defects After Trial Failure
Oct 22, 2025 • Barron's
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint
Oct 22, 2025 • Yahoo Finance
Moderna says CMV vaccine once seen as future blockbuster fails key study
Oct 22, 2025 • BioPharma Dive
Another bump in Moderna’s neoantigen road | ApexOnco - Clinical Trials news and analysis
Oct 13, 2025 • Oncology Pipeline
Should Moderna's (MRNA) Improved Revenue Trends Prompt New Action From Investors?
Oct 9, 2025 • Yahoo Finance
Moderna (MRNA): Assessing Valuation After Recent 12% Share Price Jump and Updated Financials
Oct 6, 2025 • Yahoo Finance
Moderna (MRNA) Beats Stock Market Upswing: What Investors Need to Know
Oct 2, 2025 • Yahoo Finance
Brookline Reaffirms Price Target for Moderna (MRNA) After Strong mRNA-1283 Vaccine Results
Oct 1, 2025 • Yahoo Finance
GSK’s Emma Walmsley, Pharma’s First Woman CEO, Steps Down After 9 Years
Sep 29, 2025 • BioSpace
COVID-19 Vaccination Fall 2025/2026 Implementation Package
Sep 27, 2025 • City of Hamilton
Robert F. Kennedy Jr. Faces Impeachment Push From Haley Stevens Over 'Health Care Chaos' And Rising Costs: 'Enough Is Enough'
Sep 26, 2025 • Benzinga.com
Trump’s drug tariffs are days away. Massachusetts’ pharma companies aren’t worried.
Sep 26, 2025 • Boston Globe
Moderna opens UK’s first mRNA-focused manufacturing facility in Oxfordshire
Sep 25, 2025 • BioProcess International
Moderna Launches mRNA Innovation Hub in Oxfordshire to Scale UK Vaccine Capabilities
Sep 25, 2025 • PharmiWeb
UK drug price rises necessary, says Patrick Vallance
Sep 25, 2025 • BBC
Medicine price rises ‘necessary’ to secure investments, science minister says
Sep 25, 2025 • The Independent
Moderna opens UK manufacturing and R&D facility
Sep 25, 2025 • Pharma Letter
UK boosts pandemic readiness with new vaccine factory
Sep 25, 2025 • Sky News
Moderna opens UK facility as drug pricing spat rumbles on
Sep 25, 2025 • pharmaphorum
Medicine price rises ‘necessary’ to secure investments, science minister says
Sep 25, 2025 • London Evening Standard
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK
Sep 24, 2025 • BioSpace
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
Sep 24, 2025 • BioSpace
Moderna: Updated COVID-19 vaccine generates strong immune response
Sep 23, 2025 • McKnight's Long-Term Care News
Moderna says updated next-generation COVID shot shows strong immune response in patients
Sep 23, 2025 • Reuters
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
Sep 23, 2025 • Newswire
mNEXSPIKE generates strong immune response
Sep 23, 2025 • Pharma Letter
Moderna says mNEXSPIKE generates 'strong' immune response against LP.8.1 variant
Sep 23, 2025 • thefly.com
Stocks to Watch Tuesday: TSMC, Boeing, AutoZone, Moderna
Sep 23, 2025 • Yahoo Finance
Confidence on Hold Until Powell Weighs In
Sep 23, 2025 • MarketScreener
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
Sep 23, 2025 • Morningstar.com
Moderna's COVID-19 Vaccine Update Boosts Antibodies 16-Fold, Data Shows
Sep 23, 2025 • Benzinga.com
Stocks Extend Records, Gold Soars To $3,740: What's Moving Markets Monday?
Sep 22, 2025 • Benzinga.com
On Wall Street, it's four records for the price of one
Sep 19, 2025 • MarketScreener
CDC panel votes to end universal Covid vaccine recommendation, Bloomberg says
Sep 19, 2025 • thefly.com
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
Sep 19, 2025 • PharmiWeb
Government of Canada announces major milestone in the Canadian biomanufacturing sector Français
Sep 19, 2025 • Canada NewsWire
CDC Ends Universal Covid Vaccine Recommendation; Moderna Skids
Sep 19, 2025 • Investor's Business Daily
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
Sep 19, 2025 • Morningstar.com
Moderna, Alnylam resolve patent litigation over COVID-19 vaccine delivery tech
Sep 19, 2025 • FiercePharma
Takeaways from RFK Jr.'s vaccine panel meeting on COVID-19 and childhood vaccines
Sep 19, 2025 • AP News
Government of Canada announces major milestone in the Canadian biomanufacturing sector
Sep 19, 2025 • Government of Canada
Moderna settles Alnylam patent lawsuits over COVID vaccine technology
Sep 18, 2025 • Reuters
Media advisory - Government of Canada to announce major milestone in the Canadian biomanufacturing sector Français
Sep 18, 2025 • Canada NewsWire
Government of Canada to announce major milestone in the Canadian biomanufacturing sector
Sep 18, 2025 • Government of Canada
Flagship, the firm that spawned Moderna, has a new AI startup. But it’s not for health care.
Sep 18, 2025 • Boston Globe
Moderna co-founder collects $77.5m for T.Rx Capital
Sep 18, 2025 • Venture Capital Journal
Moderna co-founder Robert Langer's son launches new VC with $77.5M, backing from dad
Sep 18, 2025 • FierceBiotech
T.Rx Capital Launches $77.5M Fund I to Invest in Bold Sta...
Sep 18, 2025 • PharmiWeb
Phase IV Trial Shows Strong Immune Response from Moderna’s Updated Spikevax Against LP.8.1 Variant of COVID-19
Sep 17, 2025 • Applied Clinical Trials Online
Moderna data show strong immune response to updated COVID vaccine
Sep 17, 2025 • CIDRAP
For lab tech trainees, the biotech industry’s promise outshines its current struggles
Sep 17, 2025 • Boston Globe
In the clinic for Sept. 17, 2025
Sep 17, 2025 • BioWorld Financial Watch
Why Moderna (MRNA) Stock Is Trading Up Today
Sep 16, 2025 • Yahoo Finance
Moderna president talks revenue and focus on new vaccine development, including cancer
Sep 16, 2025 • Fox Business
Moderna says clinical data reinforce FDA approval of 2025-2026 Spikevax formula
Sep 16, 2025 • thefly.com
Kennedy Names New ACIP Members as Panel Quiets COVID-19 Vaccine Developers Ahead of Meeting
Sep 16, 2025 • BioSpace
Vizient Recognizes Suppliers and Distributors for Service Excellence
Sep 16, 2025 • PharmiWeb
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans
Sep 16, 2025 • Newswire
WIRED Health Recap: Cancer Vaccines, CRISPR Breakthroughs, and More
Sep 15, 2025 • WIRED
Nasdaq hits record, traders await Fed meeting
Sep 13, 2025 • The Express Tribune
Nasdaq notches record high close, traders look to Fed meeting
Sep 13, 2025 • Moneycontrol
Moderna shares hit a low after report suggests the FDA plans to tie COVID shots to child deaths
Sep 13, 2025 • Fast Company
Pfizer, Moderna shares fall on report that Trump officials will link child deaths to Covid shots
Sep 12, 2025 • CNBC
Why EGI will deliver the AI revolution that matters
Sep 12, 2025 • FeliCa脆弱性問題をどう捉えるべきか | CIO
S&P 500 and Nasdaq hit records, traders look to Fed meeting
Sep 12, 2025 • MarketScreener
Nasdaq notches record high close, traders look to Fed meeting
Sep 12, 2025 • Reuters
Trump officials weigh linking child deaths to Covid vaccines; Moderna says no new safety issues after shares crack 7%
Sep 12, 2025 • Indian Express
Trump officials eye connection between COVID shots, child deaths ahead of ACIP meeting: WaPo
Sep 12, 2025 • FiercePharma
Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths
Sep 12, 2025 • Benzinga.com
Bullish flow in Moderna with shares up 4.13%
Sep 11, 2025 • thefly.com
FDA Moves To Publicize Data On Pregnant Women's Covid Vaccine Side Effects
Sep 10, 2025 • Benzinga.com
Moderna CEO Responds to RFK Jr.’s Crusade Against the Covid-19 Vaccine
Sep 9, 2025 • WIRED
Moderna’s 2025-2026 COVID-19 Vaccines Get FDA Approval
Sep 8, 2025 • Vaccine Advisor
I Thought Of Moderna, Inc. (MRNA) After Florida’s Vaccine Rules, Says Jim Cramer
Sep 7, 2025 • Yahoo Finance
As U.S. Slashes $500M in mRNA Funding, Bordeaux Biotech bYoRNA Raises €1.5M to Reinvent RNA Production
Sep 5, 2025 • The French Tech Journal